Taro Pharmaceuticals U.S.A., Inc.

4 FDA enforcement actions

4 Total Recalls

1 Class I

1 Class II

2 Class III

Firm Details

Product Types: drug
States: NY

All Recalls

Class III: Low Risk 08/07/2024 drug

Failed Impurities/Degradation Specifications: Out-of-specification results obtained for related impurities and slightly lower than the established level of the Hydrocortisone Assay obtained during stability testing.
Class III: Low Risk 02/25/2022 drug

Failed Content Uniformity Specifications: Out-of-specification result for the Betamethasone Dipropionate assay of a stability sample
Class I: Dangerous 12/15/2021 drug

Microbial Contamination of Non-Sterile Products: presence of R. Pickettii bacteria
Class II: Risk 01/08/2021 drug

CGMP deviations.

Data from FDA openFDA enforcement reports. This site is not affiliated with or endorsed by the FDA. Recall information may be updated by the FDA at any time.